Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Liabilities and Shareholders Equity (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Liabilities and Shareholders Equity data on record, last reported at $562.2 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 49.12% year-over-year to $562.2 million; the TTM value through Dec 2025 reached $2.1 billion, up 41.44%, while the annual FY2025 figure was $562.2 million, 49.12% up from the prior year.
  • Liabilities and Shareholders Equity reached $562.2 million in Q4 2025 per TARS's latest filing, up from $534.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $562.2 million in Q4 2025 and bottomed at $178.9 million in Q4 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $318.9 million, with a median of $266.9 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 106.55% in 2021, then fell 25.27% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $178.9 million in 2021, then increased by 27.36% to $227.9 million in 2022, then grew by 16.51% to $265.5 million in 2023, then surged by 42.0% to $377.0 million in 2024, then skyrocketed by 49.12% to $562.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $562.2 million in Q4 2025, $534.6 million in Q3 2025, and $495.0 million in Q2 2025.